Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 11/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.69 |
| ▸ | SLC9A5 | Q14940 | 6/20 | 0.69 |
| ▸ | TSHR | P16473 | 5/20 | 0.69 |
| ▸ | SLC9A1 | P19634 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | GLA | P06280 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 2/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829154 | 1.00 | PLAU (0.69) | PLAUCYP1A2SLC9A5TSHRSLC9A1 | |
| SCHEMBL1586403 | 1.00 | PLAU (0.69) | PLAUCYP1A2SLC9A5TSHRSLC9A1 | |
| Iodide SCHEMBL1587056 | 0.98 | PLAU (0.67) | PLAUCYP1A2SLC9A5TSHRSLC9A1 | |
| SCHEMBL14156429 | 0.88 | PLAU (0.53) | PLAUCYP1A2SLC9A5TSHRSLC9A1 | |
| SCHEMBL13104159 | 0.86 | PLAU (0.71) | PLAUCYP1A2SLC9A5TSHRSLC9A1 | |
| SCHEMBL12903457 | 0.84 | PLAU (0.64) | PLAUCYP1A2SLC9A5TSHRSLC9A1 | |
| SCHEMBL12944839 | 0.83 | PLAU (0.48) | PLAUCYP1A2SLC9A5TSHRSLC9A1 | |
| SCHEMBL14115628 | 0.83 | PLAU (0.46) | PLAUCYP1A2SLC9A5TSHRSLC9A1 | |
| SCHEMBL16200815 | 0.83 | PLAU (0.46) | PLAUCYP1A2SLC9A5TSHRSLC9A1 | |
| SCHEMBL13979955 | 0.83 | PLAU (0.68) | PLAUCYP1A2SLC9A5TSHRSLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190084943-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | PARION SCIENCES, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20170327472-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | PARION SCIENCES, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-9593084-B2 | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity | PARION SCIENCES, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20140171447-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | PARION SCIENCES, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8507497-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507497-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-1663235-B1 | CAPPED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8431579-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431579-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130060034-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | JOHNSON MICHAEL ROSS (US) | 2013-03-07 | — | — | US | disclosed |
| US-7247636-B2 | Phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247637-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247637-B2 | Capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7241766-B2 | Methods of using phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7192959-B2 | Antihistamines; antiinflammatory agents; bronchodilator agents; inflammatory bowel disorders; psoriasis | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192958-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171447-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | SCNN1B, SCNN1A, SCNN1G | PLAU 3613/4885CYP1A2 1710/4885SLC9A5 64/4885 |
| US-20170327472-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | SCNN1B, SCNN1A, SCNN1G | PLAU 3613/4885CYP1A2 1710/4885SLC9A5 64/4885 |
| US-20190084943-A1 | CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY | SCNN1B, SCNN1A, SCNN1G | PLAU 3613/4885CYP1A2 1710/4885SLC9A5 64/4885 |
| US-20070032509-A1 | New capped pyrazinoylguanidine sodium channel blockers | CACNA1B, CACNA1C, HCN4 | PLAU 3626/4885CYP1A2 3717/4885SLC9A5 119/4885 |
| US-20070021439-A1 | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers | KCNN2, KCNN1, KCNN3 | PLAU 1443/4885CYP1A2 1871/4885SLC9A5 513/4885 |
| US-20130060034-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | SCNN1G, SCNN1B, TRPV1 | PLAU 2600/4885CYP1A2 1936/4885SLC9A5 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.